The in vivo use of portable X-ray fluorescence as an alternative technique for the accompaniment of iron levels in patients with iron loading;Uso da fluorescência de raios X portátil (XRF) in vivo como técnica alternativa para acompanhamento dos níveis de ferro em pacientes com sobrecarga de ferro

Revista Brasileira de Hematologia e Hemoterapia

Volumn 31, Issue 3, 2009, Pages 153-159

  Estevam, Marcelo ^a   Appoloni, Carlos R ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Fluorescence; Iron loading; Thalassemia

Indexed keywords

EID: 77952597291     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-84842009005000043     Document Type: Article

References (42)

1. Gorodetsky R, Lowenthal E, Goldfarb A, Rachmilewitz EA. Evaluation of iron load and clearance in patients with betathalassemia. Ann. NY Acad. Sci. 1990;(612):568-72.
2. Estevam M, Malvezi AD, Borges CL, Pinge-Filho P, Appoloni CR. Evaluation of Fe employing X-Ray Fluorescence Methodology (XRF) in mice skin during acute phase of experimental infection with Trypanosoma cruzi. VI Latin American Symposium on Nuclear Physics and Applications. AIP Conf. Proc. 2007; (884): 494-6.
3. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-61.
4. MacLean DS, Robertson JD, Jay M, Stalker DJ. Noninvasive measurement of protein release from subcutaneous depo formulations in vivo using X-ray fluorescence. J Control Release. 1995;(34):167-73.
5. Shukri A, Green S, Bradley DA. A feasibility study: in vivo x-ray fluorescence of iron using 109Cd. Appl Radiat Isot. 1995; 46 (6-7):625.
6. MacLean DS, Robertson JD, Moody E, Stalker DJ, Jay M. Secondary X-ray fluorescence for in vivo transdermal absorption measurements. Int J Pharm. 1996. (131): 243-6.
7. O'Meara JM, Chettle DR, McNeill FE, Webber CE. In vivo X-ray fluorescence (XRF) measurement of uranium in bone. Appl Radiat Isot. 1998;49(5-6):713-5.
8. O'Meara JM, Börjesson J, Chettle DR. Improving the in vivo X-ray fluorescence (XRF) measurement of renal mercury. Appl Radiat Isot. 2000;53(4-5):639-46.
9. Bradley DA, Farquharson MJ. X-ray fluorescence and the in vivo evaluation of Fe, Cu and Zn in skin. J Radioanal Nucl Chem. 2000;(244):213-7
10. O'Meara JM, Börjesson J, Chettle DR, McNeill FE. Optimization of an in vivo X-ray fluorescence mercury measurement system. Nucl. Instrum. Methods Phys. Res., Sect. B. 2004;(213):560-3.
11. Ali PA, Al-Hussany AF, Bennett CA, Hancock DA, El-Sharkawi AM. Plane polarized x-ray fluorescence system for the in vivo measurement of platinum in head and neck tumours. Phys Med Biol. 1998;43(8):2337-45.
12. Shakeshaft J, Lillicrap SC. Technical note: an X-ray fluorescence system for the determination of gold in vivo following chrysotherapy. Br J Radiol. 1993;66(788):714-7.
13. Börjesson J, Barregård L, Sällsten G, Schütz A, Jonson R, Alpsten M, et al. In vivo XRF analysis of mercury: the relation between concentrations in the kidney and the urine. Phys Med Biol. 1995; 40 (3):413-26.
14. Christoffersson JO, Mattsson S. Polarised X-rays in XRF-analysis for improved in vivo detectability of cadmium in man. Phys Med Biol. 1983;28(10):1135-44.
15. Christoffersson JO, Welinder H, Spång G, Mattsson S, Skerfving S. Cadmium concentration in the kidney cortex of occupationally exposed workers measured in vivo using X-ray fluorescence analysis. Environ Res. 1987;42(2):489-99.
16. Al-Ghorabie FH, Natto SS, Al-Lyhiani SH. A comparison between EGS4 and MCNP computer modeling of an in vivo X-ray fluorescence system. Comput Biol Med. 2001;31(2):73-83.
17. Börjesson J, Mattsson S, Alpsten M. Trace element concentrations studied in vivo using X-ray fluorescence analysis. Appl. Radiat. Isot. 1998;(49):437-45.
18. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-95.
19. Michaëlsson G, Ljunghall K, Danielson BG. Zinc in epidermis and dermis in healthy subjects. Acta Derm Venereol. 1980;60 (4):295-9.
20. Molin L, Wester PO. Iron content in normal and psoriatic epidermis. Acta Derm Venereol. 1973;53(6):473-6.
21. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-73.
22. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574-8.
23. The Thalassemia Syndromes: Weatherall DJ, Clegg JB eds. Oxford, UK, Blackwell Scientific Publications, 1981.
24. Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med. 2001;111(5):349-54.
25. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95(4):1229-36.
26. Gottschalk R, Wigand R, Dietrich CF, Oremek G, Liebisch F, Hoelzer D, Kaltwasser JP. Total iron-binding capacity and serum transferrin determination under the influence of several clinical conditions. Clin Chim Acta. 2000;293(1-2):127-38.
27. de Paula EV, Saad STO, Costa FF. Quelação oral de ferro na Beta-Talassemia. Rev. bras. hematol. hemoter. 2003;1):59-63.
28. Trousseau A. Glycosurie, diabete sucre. In: Anonymous clinique medicale de l'Hotel-Dieu de Paris. 2.ed. Paris: Bailliere. 1865. p.663.
29. von Recklinghausen FD. Uber Hemochromatose. Tagebl Versamml Natur Arzte Heidelberg. 1889;(62):324.
30. Powell LW. Genetic diagnosis of hemochromatosis: implications for prophylaxis and treatment. In: Arroyo V, Bosch J, Bruguera M, editors. Therapy in liver diseases. Barcelona: Masson. 1997. p.391-404.
31. Galizzi Filho J, Andrade MO. Doença de Wilson e hemocromatose. In: Parise ER, Porta G, editores. Manual de diagnóstico e tratamento das doenças hepáticas - no paciente adulto e pediátrico. São Paulo: 1999. p.145-57.
32. Powell LW, Leggett BA, Crawford DHG. Hemochromatosis and other iron storage disorders. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff's diseases of the liver. 8a ed. Philadelphia: Lippincott/Williams & Wilkins. 1999. v. 2, p.1107-30.
33. Powell LW, Subramaniam N, Yapp TR. Haemochromatosis in the new millennium. J Hepatol. 2000; 32(1 Suppl):48-62. Review
34. de Souza AF, Carvalho-Filho RJ, Chebli JF. Hereditary hemochromatosis. Case report and review of the literature. Arq Gastroenterol. 2001;38(3):194-202.
35. Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol. 1998;35(1): 55-71.
36. Brissot P, Moirand R, Guyader D, Loréal O, Turlin B, Deugnier Y. Hemochromatosis after the gene discovery: revisiting the diagnostic strategy. J Hepatol. 1998;28(Suppl 1):14-8.
37. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology. 1992;15(4):655-9.
38. Turner JE. Atoms, Radiation, and Radiation Protection. 2. ed. New York. J. Wiley & Sons, INC. 1995. cap 12 p. 366-373.
39. Berger MJ, Hubbell JH. XCOM: photon cross section on a personal computer. 1987. NSBIR 87-3597.
40. Aragão PHA, Suguihiro NM, Dos Santos SB, Estevam M, Da Costa ECS, Di Mauro E, et al. A Study of the elements in sooty mould phytopathology by physical techniques. Microsc Microanal. 2003. (9):1538-9.
41. Aragão PH, dos Santos SB, da Costa EC, Suguihiro NM, Estevam M, Filho VF. Study of heavy metal content in HIV-infected blood using X-ray fluorescence technique. Cell Mol Biol (Noisy-le-grand). 2003; 49 Online Pub:OL415-7.
42. Estevam M, Appoloni, CR. In vivo evaluation of Fe in human skin employing X-Ray Fluorescence Methodology (XRF). VI Latin American Symposium on Nuclear Physics and Applications. AIP Conf. Proc. 2007;(884):468-70.